See more : Skeena Resources Limited (SKE.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Rigel Pharmaceuticals, Inc. (RIGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rigel Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- International Game Technology PLC (IGT) Income Statement Analysis – Financial Results
- GHCL Textiles Limited (GHCLTEXTIL.NS) Income Statement Analysis – Financial Results
- Innovative Designs, Inc. (IVDN) Income Statement Analysis – Financial Results
- UEX Corporation (UEX.TO) Income Statement Analysis – Financial Results
- Yokowo Co., Ltd. (6800.T) Income Statement Analysis – Financial Results
Rigel Pharmaceuticals, Inc. (RIGL)
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 116.88M | 120.24M | 149.24M | 108.62M | 59.29M | 44.51M | 4.48M | 20.38M | 28.90M | 8.25M | 7.15M | 2.25M | 4.75M | 125.00M | 750.00K | 0.00 | 12.60M | 33.47M | 16.53M | 4.73M | 11.06M | 15.79M | 15.30M | 13.22M | 8.98M |
Cost of Revenue | 7.11M | 1.75M | 1.08M | 895.00K | 906.00K | 287.00K | 46.27M | 63.45M | 62.83M | 67.70M | 75.33M | 78.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7.56M | -1.91M |
Gross Profit | 109.77M | 118.49M | 148.15M | 107.73M | 58.38M | 44.22M | -41.79M | -43.06M | -33.93M | -59.45M | -68.18M | -76.53M | 4.75M | 125.00M | 750.00K | 0.00 | 12.60M | 33.47M | 16.53M | 4.73M | 11.06M | 15.79M | 15.30M | 20.78M | 10.89M |
Gross Profit Ratio | 93.92% | 98.55% | 99.27% | 99.18% | 98.47% | 99.36% | -931.87% | -211.27% | -117.43% | -720.56% | -953.54% | -3,401.24% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 157.17% | 121.22% |
Research & Development | 24.52M | 60.27M | 65.24M | 60.10M | 52.89M | 46.90M | 46.27M | 63.45M | 62.83M | 67.70M | 75.33M | 78.78M | 69.35M | 64.39M | 90.74M | 109.67M | 70.36M | 56.97M | 52.04M | 48.52M | 43.36M | 43.35M | 32.31M | 32.03M | 17.11M |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 70.00M | 37.83M | 20.91M | 17.81M | 31.80M | 19.61M | 22.85M | 21.77M | 25.29M | 20.90M | 27.04M | 21.76M | 19.55M | 12.41M | 13.08M | 8.52M | 9.45M | 7.95M | 6.69M | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 105.74M | 112.45M | 91.89M | 76.60M | 74.59M | 70.00M | 37.83M | 20.91M | 17.81M | 31.80M | 19.61M | 22.85M | 21.77M | 25.29M | 20.90M | 27.04M | 21.76M | 19.55M | 12.41M | 13.08M | 8.52M | 9.45M | 7.95M | 6.69M | 3.95M |
Other Expenses | 0.00 | 1.32M | 3.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.56M | 1.91M |
Operating Expenses | 130.26M | 172.72M | 157.13M | 136.70M | 127.47M | 116.91M | 84.10M | 84.35M | 80.64M | 99.50M | 94.94M | 101.63M | 91.12M | 89.68M | 111.65M | 136.71M | 92.13M | 76.52M | 64.45M | 61.60M | 51.88M | 52.80M | 40.26M | 46.28M | 22.97M |
Cost & Expenses | 137.37M | 174.47M | 158.21M | 137.59M | 128.38M | 117.19M | 84.10M | 84.35M | 80.64M | 99.50M | 94.94M | 101.63M | 91.12M | 89.68M | 111.65M | 136.71M | 92.13M | 76.52M | 64.45M | 61.60M | 51.88M | 52.80M | 40.26M | 38.72M | 21.06M |
Interest Income | 2.27M | 684.00K | 47.00K | 582.00K | 2.53M | 2.20M | 892.00K | 437.00K | 222.00K | 243.00K | 442.00K | 537.00K | 420.00K | 303.00K | 600.00K | 4.44M | 5.48M | 5.70M | 2.94M | 966.00K | 374.00K | 856.00K | 1.96M | 1.08M | 0.00 |
Interest Expense | 6.87M | 3.71M | 4.86M | 1.35M | 335.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.00K | 17.00K | 25.00K | 91.00K | 203.00K | 160.00K | 221.00K | 290.00K | 276.00K | 324.00K | 575.00K | 870.00K | 802.00K | 933.00K | 0.00 |
Depreciation & Amortization | 1.24M | 998.00K | 1.16M | 706.00K | 683.00K | 594.00K | 465.00K | 941.00K | 1.44M | 2.36M | 2.59M | 2.43M | 1.96M | 1.32M | 1.40M | 1.43M | 1.34M | 1.42M | 1.18M | 2.37M | 3.18M | 5.82M | 6.76M | 7.56M | 1.91M |
EBITDA | -16.98M | -53.87M | -11.29M | -27.69M | -65.88M | -69.89M | -77.53M | -63.03M | -50.30M | -88.89M | -85.20M | -96.94M | -83.99M | 39.30M | -110.03M | -130.85M | -79.53M | -43.05M | -47.92M | -54.49M | -37.65M | -31.19M | -18.20M | -17.95M | -10.17M |
EBITDA Ratio | -14.53% | -44.53% | -5.98% | -26.14% | -112.26% | -163.30% | -1,791.88% | -285.97% | -179.27% | -1,107.24% | -1,185.40% | -4,416.76% | -1,768.27% | 29.55% | -14,519.07% | 0.00% | -620.50% | -124.37% | -282.84% | -1,150.73% | -339.04% | -197.57% | -118.93% | -135.78% | -113.25% |
Operating Income | -20.49M | -54.23M | -8.98M | -28.97M | -69.09M | -72.68M | -79.62M | -69.74M | -51.74M | -91.25M | -89.47M | -99.38M | -86.37M | 35.32M | -112.04M | -136.71M | -79.53M | -43.05M | -47.92M | -56.87M | -40.83M | -37.02M | -24.96M | -25.51M | -12.08M |
Operating Income Ratio | -17.53% | -45.10% | -6.01% | -26.67% | -116.53% | -163.30% | -1,775.56% | -342.15% | -179.07% | -1,106.05% | -1,251.31% | -4,416.76% | -1,818.27% | 28.25% | -14,938.27% | 0.00% | -631.17% | -128.60% | -289.98% | -1,201.50% | -369.31% | -234.46% | -163.11% | -192.96% | -134.46% |
Total Other Income/Expenses | -4.60M | -3.02M | -4.81M | -771.00K | 2.20M | 2.20M | 1.62M | 525.00K | 279.00K | 341.00K | 442.00K | 537.00K | 395.00K | 2.57M | 397.00K | 4.28M | 5.26M | 5.41M | 2.67M | 612.00K | -370.00K | -14.00K | 1.16M | 145.00K | 0.00 |
Income Before Tax | -25.09M | -58.57M | -17.31M | -29.74M | -66.89M | -70.48M | -77.99M | -69.22M | -51.46M | -90.91M | -89.03M | -98.84M | -85.97M | 37.89M | -111.64M | -132.44M | -74.27M | -37.64M | -45.26M | -56.26M | -41.20M | -37.03M | -23.81M | -25.36M | 0.00 |
Income Before Tax Ratio | -21.47% | -48.71% | -11.60% | -27.38% | -112.83% | -158.35% | -1,739.34% | -339.58% | -178.11% | -1,101.92% | -1,245.13% | -4,392.89% | -1,809.96% | 30.31% | -14,885.33% | 0.00% | -589.46% | -112.44% | -273.85% | -1,188.57% | -372.65% | -234.55% | -155.56% | -191.86% | 0.00% |
Income Tax Expense | 0.00 | 3.02M | 605.00K | 647.00K | -348.00K | 2.20M | -2.09M | 4.30M | -1.72M | -2.70M | 0.00 | -2.43M | 420.00K | 91.00K | -93.00K | -89.00K | 0.00 | 0.00 | 0.00 | -612.00K | 370.00K | 0.00 | 0.00 | 0.00 | 286.00K |
Net Income | -25.09M | -61.60M | -17.91M | -30.39M | -66.55M | -70.48M | -77.99M | -69.22M | -51.46M | -90.91M | -89.03M | -98.84M | -85.97M | 37.89M | -111.55M | -132.35M | -74.27M | -37.64M | -45.26M | -56.26M | -41.20M | -37.03M | -23.81M | -25.36M | -12.37M |
Net Income Ratio | -21.47% | -51.23% | -12.00% | -27.98% | -112.24% | -158.35% | -1,739.34% | -339.58% | -178.11% | -1,101.92% | -1,245.13% | -4,392.89% | -1,809.96% | 30.31% | -14,872.93% | 0.00% | -589.46% | -112.44% | -273.85% | -1,188.57% | -372.65% | -234.55% | -155.56% | -191.86% | -137.64% |
EPS | -1.44 | -3.40 | -1.05 | -1.76 | -4.00 | -4.39 | -6.17 | -7.33 | -5.82 | -10.37 | -10.20 | -1.32 | -1.36 | 0.73 | -2.73 | -3.67 | -2.57 | -1.51 | -2.07 | -3.12 | -3.62 | -66.73 | -5.75 | -31.43 | -355.49 |
EPS Diluted | -1.44 | -3.40 | -1.05 | -1.76 | -4.00 | -4.39 | -6.17 | -7.33 | -5.82 | -10.37 | -10.20 | -1.32 | -1.36 | 0.72 | -2.73 | -3.67 | -2.57 | -1.51 | -2.07 | -3.12 | -3.62 | -66.73 | -5.75 | -31.43 | -355.49 |
Weighted Avg Shares Out | 17.40M | 17.24M | 17.05M | 16.88M | 16.72M | 16.05M | 12.63M | 9.44M | 8.84M | 8.77M | 8.73M | 74.88M | 63.33M | 52.06M | 40.88M | 36.03M | 28.94M | 24.94M | 21.86M | 18.05M | 11.40M | 554.94K | 4.14M | 806.92K | 34.79K |
Weighted Avg Shares Out (Dil) | 17.40M | 17.24M | 17.05M | 16.88M | 16.74M | 16.05M | 12.63M | 9.44M | 8.84M | 8.77M | 8.73M | 74.97M | 63.33M | 52.57M | 40.88M | 36.03M | 28.94M | 24.94M | 21.86M | 18.05M | 11.40M | 554.94K | 4.14M | 806.92K | 34.79K |
Rigel Announces Conference Call and Webcast to Report First Quarter 2023 Financial Results and Business Update
4 Top Penny Stocks To Watch With Big Biotech News This Quarter
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2022 Earnings Call Transcript
Rigel Pharmaceuticals (RIGL) Q4 Earnings and Revenues Surpass Estimates
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2022 Financial Results and Business Update
Rigel Pharmaceuticals: A Strong Finish To 2022 And A Potentially Transformative 2023
Optime Care, Specialty Pharmacy Patient Management Organization Announces Enhanced Partnership with Rigel Pharmaceuticals, Inc. for Rezlidhia™ Patients
Don't Invest in Penny Stocks Until You've Read This Article
Rigel (RIGL) Up on FDA Nod to Blood Cancer Drug Rezlidhia
Rigel Pharmaceuticals (RIGL) Stock Soars on FDA Approval News
Source: https://incomestatements.info
Category: Stock Reports